-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Emavusertib Hydrochloride in Secondary CNS Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Emavusertib Hydrochloride in Secondary CNS Lymphoma Drug Details: Emavusertib hydrochloride is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Emavusertib Hydrochloride in Refractory Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Emavusertib Hydrochloride in Refractory Acute Myeloid Leukemia Drug Details: Emavusertib hydrochloride is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Emavusertib Hydrochloride in Relapsed Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Emavusertib Hydrochloride in Relapsed Acute Myeloid Leukemia Drug Details: Emavusertib hydrochloride is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Brexanolone in Sleep Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Brexanolone in Sleep Disorders report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Brexanolone in Sleep Disorders Drug Details: Brexanolone is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Inobrodib in Peripheral T-Cell Lymphomas (PTCL)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Inobrodib in Peripheral T-Cell Lymphomas (PTCL) Drug Details: Inobrodib (CCS-1477) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy For Relapsed And Refractory Multiple Myeloma in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy For Relapsed And Refractory Multiple Myeloma in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gene Therapy For...
-
Product Insights
Primary CNS Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Primary CNS Lymphoma - Drugs In Development, 2023’, provides an overview of the Primary CNS Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary CNS Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) - Drugs In Development, 2023’, provides an overview of the Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Cutaneous T-Cell Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Cutaneous T-Cell Lymphoma - Drugs In Development, 2023’, provides an overview of the Cutaneous T-Cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cutaneous T-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Drugs In Development, 2023’, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...